Sector consensus Legend Biotech Corporation
Equities
LEGN
US52490G1022
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.32 USD | -3.00% |
|
-20.65% | -31.41% |
| 12-10 | Legend Biotech's Stock Weakness After Rival Treatment Update 'Overdone,' RBC Says | MT |
| 12-08 | UBS Adjusts Legend Biotech Price Target to $48 From $54, Maintains Buy Rating | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | US$72.31 | +223.95% | 15 | ||||||
| €797.32 | +5.86% | 13 | ||||||
| US$224.89 | +14.15% | 18 | ||||||
| CN¥126.08 | +34.06% | 19 | ||||||
| US$118.09 | +46.4% | 19 | ||||||
| DKK 2,083.23 | +3.39% | 14 | ||||||
| HK$35.84 | +18.09% | 25 | ||||||
| HK$155.28 | +37.31% | 21 | ||||||
| US$24.26 | +82.58% | 13 | ||||||
| HK$532.56 | +21.42% | 17 | ||||||
| US$571.13 | -0.05% | 15 | ||||||
| US$44.94 | +9.94% | 18 | ||||||
| US$61.58 | -12.14% | 12 | ||||||
| US$141.82 | +35.33% | 17 | ||||||
| US$79.56 | +25.58% | 18 | ||||||
| - | - | - | - | - | ||||
| - | US$97 | +0.07% | 12 | |||||
| Average | 322.87 | +34.12% | 17 | ||||||
| Weighted average by Cap. | 410.75 | +23.68% | 17 |
- Stock Market
- Equities
- LEGN Stock
- Sector Legend Biotech Corporation
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition